[Therapeutic Monitoring Plasma Imatinib to Improve Results of the Treatment of Chronic Myeloleukosis].

Abstract

The achievement of early cytogenetic and molecular responses is the major objective of therapy and a main prerequisite for the favourable long-term outcome of the disease. The maintenance of dose intensity and management of adverse events are keys to successful treatment of chronic myeloid leukemia (CML) with imatinib. Therapeutic monitoring and testing the drug level in blood are the efficient tools for the treatment of patients with CML and can be usedfor analysis of treatment failure or suboptimal response to therapy, suspected noncompliance, drug interactions or unexpected adverse reactions.